文档介绍：第 19 卷第 11 期临床药物治疗杂志，
hinese Medical Institutions，Mini HTA of Evo⁃
locumab and Alirocumab was carried out in terms of pharmaceutical characteristics，effectiveness，safety，economy and other
attributes by consulting literature，guidelines，instructions，drug trading and procurement platform，essential drugs and medical
insurance catalogue. Results The final scores of Evolocumab and Alirocumab were 80. 3 and 73. 5，respectively. Compared
with Evolocumab，Alirocumab has a shorter time on the market and less clinical experience. Evolocumab could be adminis⁃
tered once every 2 weeks or once a month；Alirocumab should be administered only once every 2 weeks. Evolocumab was su⁃
perior to Alirocumab in safety and economy. Conclution Evolocumab and Alirocumab are strong recommendations for drug
selection in medical institutions.
【Key words】 PCSK9 Inhibitor；Evolocumab；Alirocumab；mini health technology assessment；drug selection
卫生技术评估（health technology assessment，际需求的卫生技术评估，是为医院决策者遴选药品、
HTA）是一种综合的政策研究形式，旨在为决策者制引入医疗技术设备等提供参考依据［1］。动脉粥样硬
定循证政策提供科学依据［1］。Mini 卫生技术评估化性心血管疾病（atherosclerotic cardiovascular dis⁃
（Mini HTA）是在传统 HTA 基础上发展的基于医院实